is an alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma. Clinical benefit is more prominent in patients with methylation of the O(6) -methyl-guanine DNA methyltransferase (MGMT) promoter. However, all patients eventually suffer from tumor progression because their tumors become resistant to TMZ. Here, we modeled acquired TMZ resistance in glioma cells in vitro to identify underlying molecular mechanisms. To this end, the glioma cell lines LNT-229, LN-308, and LN-18 were exposed repetitively to increasing concentrations of TMZ to induce a stable resistant phenotype (R) defined by clonogenic survival assays. The molecular mechanisms mediating acquired resistance were assessed by immunoblot, PCR, and flow cytometry. Rescue experiments were performed with siRNA-mediated candidate gene silencing. We found in LN-18 cells constitutively expressing MGMT a strong up-regulation of MGMT levels in TMZ-resistant cells. TMZ resistance in the MGMT-negative cell lines LNT-229 and LN-308 was not associated with de novo expression of MGMT. Instead, we found a down-regulation of several DNA mismatch-repair proteins in resistant LNT-229 cells. A TMZ-resistant phenotype was also achieved by silencing selected DNA mismatch repair proteins in parental LNT-229 cells. No obvious mechanism of resistance was identified in the third cell line, LN-308, except for reduced methylation of LINE-1 repetitive elements. In conclusion, we demonstrate that different molecular mechanisms may contribute to the development of acquired TMZ resistance in glioma cells, indicating the need to develop distinct strategies to overcome resistance. 
However, all patients eventually suffer from tumor progression because their tumors become resistant to TMZ. Here, we modelled acquired TMZ resistance in glioma cells in vitro to identify underlying molecular mechanisms. To this end, the glioma cell lines LNT-229, LN-308 and LN-18 were exposed repetitively to increasing concentrations of TMZ to induce a stable resistant phenotype (R) defined by clonogenic survival assays. The molecular mechanisms mediating acquired resistance were assessed by immunoblot, PCR and flow cytometry. Rescue experiments were performed with siRNA-mediated candidate gene silencing. We found in LN-18 cells constitutively expressing MGMT a strong up-regulation of MGMT levels in TMZ-resistant cells.
TMZ resistance in the MGMT-negative cell lines LNT-229 and LN-308 was not associated with de novo expression of MGMT. Instead, we found a down-regulation of several DNA mismatch-repair proteins in resistant LNT-229 cells. A TMZ-resistant phenotype was also achieved by silencing selected DNA mismatch repair proteins in parental LNT-229 cells. No obvious mechanism of resistance was identified in the third cell line, LN-308, except for reduced methylation of LINE-1 repetitive elements.
In conclusion, we demonstrate that different molecular mechanisms may contribute to the development of acquired TMZ resistance in glioma cells, indicating the need to develop distinct strategies to overcome resistance. TSA, trichostatin A.
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INTRODUCTION
Despite recent therapeutic advances, the prognosis of patients afflicted by glioblastoma remains poor, with a progression-free survival in the range of months, even with multimodal therapy including surgery, radio-and chemotherapy.
Temozolomide (TMZ), an oral alkylating agent, has demonstrated activity against recurrent and newly diagnosed glioblastoma and is being used as the standard of care since 2000 respectively 2005 (Yung et al. 2000 , Stupp et al. 2005 .
The DNA repair protein O 6 -methylguanine methyltransferase (MGMT) removes O 6 -alkyl-guanine adducts from DNA through irreversible binding and degradation, thereby minimizing the DNA-damaging effects of alkylating agent chemotherapy (Wang et al. 1996 , Phillips et al. 1997 . Accordingly, pharmacological inhibition of MGMT promotes antitumor activity of alkylating agents such as TMZ both in vitro and in vivo (Dolan et al. 1991 , Wedge et al. 1996 . Epigenetic silencing of the MGMT gene in tumor cells by methylation of its promoter had been associated with glioma sensitivity to alkylating chemotherapy (Esteller et al. 2000) and has been identified as a predictive biomarker for benefit from TMZ in patients with newly diagnosed glioblastoma (Hegi et al. 2005 , Weller et al. 2010 .
However, even patients with initial tumor control will inevitably relapse or progress during or after TMZ therapy. Thus, both constitutive and acquired glioma cell resistance to alkylating chemotherapy are major clinical challenges. A better understanding of the underlying mechanisms may allow for a more durable benefit from the anti-glioma properties of TMZ.
In contrast to its role in primary chemoresistance, the role of MGMT in acquired resistance to TMZ has only partially been assessed. Few, if any, patients exhibit a change of MGMT promoter methylation status at progression , Christmann et al. 2010 , Felsberg et al. 2011 .
Another DNA repair system that has been proposed to mediate chemoresistance in various tumor cells is the DNA mismatch repair (MMR) system, which consists of several enzymes. The role of deficient MMR has been addressed in most detail in colon cancer. Here, MMR mutations cause genetic predisposition associated with an increased risk for colon cancer (Bronner et al. 1994 , Papadopoulos et al. 1994 . The MMR system recognizes and repairs base mismatches after DNA replication, mostly mediated by two heterodimers of MutS homologues, MutS-α (MSH2/MSH6
heterodimer) for small insertion/deletion loops and MutS-β (MSH2/MSH3
heterodimer) for large insertion/deletion loops (Genschel et al. 1998) . Colon carcinoma cells are up to 60x more resistant to alkylating agent chemotherapy when the MMR genes are mutated (Liu et al. 1996) .
In human gliomas, the expression of 6 MMR proteins has been detected. Their role has not been well elucidated yet. While some reports postulate that an overexpression of MMR proteins exerts oncogenic effects, most probably by continuous DNA repair promoting survival (Rellecke et al. 2004) , other authors have shown that a defective MMR system may favor tumor growth and chemoresistance. It is assumed that a lack of correct DNA replication leads to an accumulation of DNA damage and subsequent tumor growth (Yip et al. 2009 ).
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MATERIALS AND METHODS
Materials and cell lines
All glioma cell lines were kindly provided by Dr. N. de Tribolet (Lausanne, Switzerland). TMZ-resistant cells were generated by repetitive pulse exposure of LNT-229, LN-308 and LN-18 glioma cells to TMZ (24 h exposure every 2 weeks).
Increasing concentrations of TMZ were applied over 6 months under consideration of the respective EC 50 values (Hermisson et al. 2006) , with selection and culturing of the resistant surviving cell fraction of each passage and consecutive re-exposure to a TMZ pulse after confluent growth. The derived resistant cell lines are further referred to as LNT-229_R, LN-308_R and LN-18_R. All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FCS, 2 mM glutamine and penicillin (100 IU/ml)/streptomycin (100 µg/ml). TMZ was provided by ScheringPlough (Kenilworth, NJ, USA). A stock solution of TMZ at 50 mM was prepared in dimethylsulfoxide (DMSO) and stored at -20°C. Propidium iodide (PI), trichostatin A and all other reagents, unless indicated otherwise, were purchased from Sigma (St.
Louis, MO, USA).
Viability and clonogenic assays
Proliferation was assessed by obtaining viable cell counts using trypan blue dye exclusion. For cytotoxicity assays, 5 x 10 3 cells were seeded per well in 96-well plates, allowed to attach for 24 h, and exposed to TMZ as indicated for 72 h in serum-free medium. Clonogenic assays were performed by seeding 10 2 cells for LNT-229 and LN-18 or 3 x 10 2 cells for LN-308 per well in 96-well plates. After 24 h, the cells were exposed to TMZ as indicated for 24 h in serum-free medium, followed by observation for 7-14 days in FCS-containing medium. For both assays, cell density was assessed by crystal violet staining of adherent cells.
Immunoblot analyses
The cells were treated with TMZ or DSMO vehicle and lysed in lysis buffer containing 2 µg/ml Aprotinin, 10 µg/ml Leupeptin and 100 µg/ml PMSF (Sigma 
DNA mutation and methylation analyses
For methylation-specific PCR (MSP) analysis of the MGMT promoter, 2 pairs of primers, each specific for either the methylated or the unmethylated promoter region, were used. Primer sequences for the unmethylated sequence were fwd: 5′-TTT GTG TTT TGA TGT TTG TAG GTT TTT GT-3′ and rv: 5′-AAC TCC ACA CTC TTC CAA AAA CAA AAC A-3′, and for the methylated sequence fwd: 5′-TTT CGA CGT TCG TAG GTT TTC GC-3′ and rv: 5′-GCA CTC TTC CGA AAA CGA AAC G-3′. The MSP reactions were prepared in a total volume of 25 µl using HotStarTaq® Master Mix Kit (Qiagen, Hilden, Germany). For PCR, 1.8 µl of bisulfite-modified DNA were added and subjected to 36 PCR cycles with denaturation at 94°C for 30 sec, primer annealing at 59°C for 40 sec, extension at 72°C for 2 min and a final extension for 10 min. PCR products were separated using Spreadex® EL 600 or 800 gels (Elchrom Scientific AG, Cham, Switzerland) and loaded with 3-5 µl of the respective PCR product. Electrophoresis was carried out at 120 V and 55°C for 40 min. Amplicons were visualized using SYBR® Gold (Molecular Probes, OR) (Felsberg et al. 2009 ). In addition, MGMT promoter methylation was assessed by DNA pyrosequencing as reported (Felsberg et al. 2011) .
Methylation analyses of the MLH1, MSH2, MSH6 and PMS2 gene promoters were assessed by DNA pyrosequencing as described (Felsberg et al. 2011 ). In addition,
we investigated exons 1 to 10 of MSH6 for mutation using single-strand conformation polymorphism (SSCP) analysis followed by direct sequencing (Reifenberger et al. 1996) . The respective primer sequences are available on request. The methylation level of LINE-1 (GenBank accession number X58075) was also assessed by DNA pyrosequencing using the PyroMark LINE-1 kit (Qiagen, Hilden, Germany) and the PyroMark Q24 sequencer (Qiagen).
Reporter assay
Dual luciferase/renilla assays were carried out with co-transfection of 150 ng of the 
Data analysis
Data are representative of experiments performed three times with similar results.
Viability and proliferation studies were performed using triplicate wells. Where indicated, analysis of significance was performed using the two-tailed Student's t-test.
RESULTS
Repeated exposure to TMZ induces resistance in human glioma cells
LNT-229, LN-308 and LN-18 glioma cells were pulse-exposed to increasing concentrations of TMZ for 6 months until a stable resistant phenotype was observed.
No change in cellular morphology was observed by light microscopy (Supplementary MGMT is consumed in response to DNA damage by proteasomal degradation after removal of an alkyl group from the DNA (Srivenugopal et al. 1996) . Both parental LN-18 and LN-18_R cells displayed a concentration-dependent loss of MGMT protein levels after exposure to TMZ. However, LN-18_R cells still retained MGMT levels after exposure to TMZ at 1000 µM that were similar to untreated parental cells ( Figure 2B ).
We next asked whether increased MGMT expression was responsible for induced 
p21 displays altered expression in resistant LN-18_R cells
p21 is one of the major regulators of the cell cycle and has previously been linked to resistance to apoptosis in glioma cells (Naumann et al. 1998 , Glaser et al. 2001 ).
Real-time PCR and immunoblot revealed elevated p21 mRNA and protein levels in untreated LN-18_R, but not in LNT-229_R or LN-308_R cells ( Figure 4A , B).
Moreover, exposure to TMZ strongly up-regulated p21 mRNA levels in LN-18_R cells ( Figure 4C ), but not in LNT-229_R or LN-308_R (data not shown). Accordingly, the doubling time in LN-18_R cells was distinctively reduced (Supplementary Figure 2) .
In contrast to p21, no significant changes were observed for ATM, ATR, p27 or cyclin D in either cell line (Supplementary Figure 5) . Since LN-18 cells express a mutant p53 protein (Wischhusen et al. 2003) , the induction of p21 expression is independent of p53. We also considered the possibility that the increased p21 levels were responsible for slowed cell cycle progression in LN-18-R cells. Accordingly, we silenced p21 expression in LN-18 or LN-18-R cells using siRNA. Interestingly, the main effect of silencing p21 was the acute induction of cell death rather than an altered cell cycle distribution, and the extent of cell death induction was more prominent in LN-18-R cells which expressed more p21 (37.5% versus 24.2%) (Supplementary Figure 6) . Thus, a role for p21 specifically in cell cycle progression could not be confirmed.
MMR protein down-regulation is important for TMZ-resistance in LNT-229-R
Reduced levels of MMR proteins may promote resistance to alkylating agents, but their role in gliomas has remained controversial. While no significant changes in the mRNA expression and protein levels of MLH1, MSH2, MSH3, MSH6, PMS1 and 
Acquired resistance to TMZ changes chromatin organization in LNT-229 cells
It has been reported that TMZ induces heterochromatin reorganization in glioma cells (Papait et al. 2009 ). Heterochromatin is characterized by lower levels of acetylated core histones and higher levels of methylated histones, e.g., trimethylated H3K9.
Immunoblots of parental and TMZ-resistant glioma cell lines revealed lower levels of acetylated H3 histones but higher levels of H3K9 trimethylated histones in resistant as opposed to parental LNT-229_R cells ( Figure 6A ), suggesting that a shift from a more euchromatin-to a more heterochromatin-centered status might contribute to the 
Decreased global DNA methylation levels indicated by LINE-1 methylation in LN-308_R and LN-18_R cells
Long interspersed nuclear element-1 (LINE-1) is a human retrotransposon that has been proposed to create DNA double-strand breaks with genome-destabilizing effects and may be associated with G2/M arrest in cancer cells (Gasior et al. 2006 , Belgnaoui et al. 2006 . In most normal cells, LINE-1 sequences are silenced by methylation, whereas in cancer cells, LINE-1 may be overexpressed (Asch et al. 1996 , Bratthauer & Fanning 1992 . Since LINE-1 accounts for approximately 18% of the human genome, its methylation status represents a surrogate indicator of global DNA methylation. Recent data suggested the LINE-1 methylation status as a better prognostic marker in glioblastoma patients than the MGMT promoter methylation status (Ohka et al. 2011) . We investigated whether the methylation levels of LINE-1 differ between parental and TMZ-resistant glioma cells. We found a significant reduction of methylation in resistant LN-308_R and LN-18_R cells relative to the respective parental cells, suggesting that reduced global DNA methylation may be involved in the acquired resistance to TMZ ( Figure 6B ).
Alkylpurine-DNA-N-glycosylase (APNG) levels are not induced in resistant glioma cell lines
APNG is an enzyme that repairs the cytotoxic lesions N 3 -methyladenine and N 7 -methylguanine, and may contribute to TMZ resistance in glioblastoma (Agnihotri et al. 2012 ). Accordingly, we performed PCR and immunoblot analyses to measure APNG levels, but found these to be unaltered in the resistant as compared to the
DISCUSSION
Responsiveness to cytotoxic therapies defined by radiological responses or at least radiologically defined stable disease is commonly of short duration in malignant glioma patients. This is also true for many patients expected to derive benefit from alkylating agent chemotherapies because of MGMT promoter methylation (Hegi et al. 2005 , Weller et al. 2010 . The mechanisms leading to acquired resistance to TMZ are incompletely understood. Here, we generated TMZ-resistant glioma cell lines by repetitive exposure to increasing TMZ concentrations. Although this approach may not closely reflect the situation in vivo, it allows for an assessment of mechanisms triggered by repeated pulse exposure to TMZ.
First, we demonstrated that TMZ resistance can be induced in different glioma cell lines, independently of the MGMT promoter methylation status: the EC 50 values increased up to 10-fold in resistant cells (Figure 1 ). Given the prominent role of MGMT in determining sensitivity to alkylating agent chemotherapy, it would be tempting to speculate that resistant subclones generated from MGMT promotermethylated cell lines exhibit a loss of promoter methylation and de novo expression of MGMT. Yet, this was not the case (Figure 2A) , consistent with the analysis of paired recurrent and primary tumor specimens in vivo which confirmed a stable MGMT status at recurrence in the vast majority of patients (Felsberg et al. 2011 ). We also investigated whether constitutively MGMT-positive LN-18 cells exhibit changes in MGMT levels when induced to become even more TMZ-resistant. Since MGMT is consumed when counteracting TMZ-induced DNA damage, the intracellular levels of MGMT are predicted to correlate with chemoresistance. In fact, we found a striking increase in MGMT mRNA and protein in TMZ-resistant LN-18 cells. Not surprisingly, LN-18_R cells exhibited cross-resistance to another alkylator, lomustine, which was not found in the MGMT-negative resistant cells that had developed MGMT-independent pathways of resistance (Supplementary Figure 4) . Immunoblot analyses revealed that MGMT levels were increased to a quantity high enough in resistant LN-18_R to still have similar levels of MGMT after exposure to 1000 µM TMZ as untreated parental cells ( Figure 2B ). Considering that the median serum concentration measured in patients treated with TMZ at 150 mg/m 2 in clinical settings corresponds to 50 µM (Hammond et al. 1999) , it becomes clear how this gain in MGMT levels may confer acquired resistance. Depletion of MGMT with O 6 -BG largely restored TMZ sensitivity although the resistance of LN-18_R remained slightly above that of parental cells, underlining that chemoresistance is multimodal and involves more than one pathway. One additional mechanism operating in LN-18_R cells identified here is an induction of p21, a key regulator of cell cycle progression (Fig. 4) previously linked to apoptosis resistance in glioma cells (Naumann et al. 1998 , Glaser et al. 2001 . Admittedly, even with O 6 -BG, the concentrations required to inhibit LN-18 growth in vitro exceeded the TMZ concentrations achieved in vivo,
suggesting that the study of primarily MGMT promoter-methylated cell lines such as LNT-229 and LN-308 acquiring resistance is the more relevant paradigm.
It has been previously reported that exposure to TMZ induces cell cycle arrest rather than cell death in glioma cells (Hirose et al. 2001) . progression that may lead to G1-, G2-or S-phase arrest (Ogryzko et al. 1997) . In resistant LN-18_R cells, p21 was overexpressed up to 5-fold, likely accounting for cell cycle slowing and escape from cell death, and matching the observed slower growth of resistant LN-18_R in culture in proliferation assays (Supplementary Figure   2 ). An even more distinct increase in p21 mRNA levels was seen in LN-18_R when exposed to TMZ, corroborating the role of this cyclin-dependent kinase inhibitor for cell survival in resistant LN-18_R cells. These results are consistent with an increase in p21 levels as a resistance mechanism leading to a G2 arrest without induction of apoptosis in glioma cells after p53 gene transfer (Gomez-Manzano et al. 1997) .
After having ruled out that demethylation of the MGMT promoter accounted for acquired resistance in the MGMT promoter-methylated cell lines, we investigated whether MMR protein levels varied between parental and resistant cells. To date, literature on MMR in glioma has remained inconsistent. While some findings indicate a role for cellular resistance being associated with MMR deregulation (Yip et al. 2009 ), others reported no significant impact of MMR on resistance (Maxwell et al. 2008) . Here, we found that, while no significant change in MMR levels was found in LN-18_R or LN-308_R cells (Supplementary Figure 7) , LNT-229_R exhibited a strong down-regulation of all 6 investigated MMR proteins in TMZ-resistant cells.
Experiments with siRNA-mediated knockdown proved that MMR gene silencing mediates resistance to TMZ in LNT-229 parental cells for MSH2, MSH6 and PMS2, all of them involved in the formation and heterodimerization of the α-subunit of MutS and MutL, respectively, both more relevant for base repair than the β-subunit. This is in accordance with former investigations on colon carcinoma cells where TMZ resistance increased in MMR-deficient cells (Liu et al. 1996) . Most importantly, a single protein knockdown transiently around the time of the TMZ application was sufficient to induce resistance in formerly sensitive cells. Interestingly, these data are consistent with recent findings of reduced MMR protein levels in patient tissue from glioblastoma at recurrence, identifying the same 3 MMR proteins, MSH2, MSH6 and PMS2, as being significantly down-regulated in patients at tumor recurrence (Felsberg et al. 2011) . Acquired methylation of the respective MMR gene promoters does not account for the reduced expression of MMR mRNA and protein as investigated by methylation-specific PCR in our cell lines as well as in primary and recurrent glioblastoma primary tissues (Felsberg et al. 2011) . Moreover, using TSA treatment, we also detected no evidence that altered histone acetylation contributes to the observed down-regulation of MMR genes in LNT-229_R, albeit these cells displayed a globally reduced acetylation and increased methylation of histone H3.
The latter finding may point to a role of epigenetic gene regulation in the acquired TMZ resistance of this cell line, however, the potentially affected genes need to be identified.
None of the above-mentioned resistance mechanisms appeared to be operating in LN-308 cells. We found a potential role for reduced methylation of LINE-1 sequences in LN-308_R and LN-18_R cells, suggesting reduced global DNA methylation that might lead to reduced DNA stability as a probable resistance mechanism. In LN-18_R, this effect could contribute to the cell cycle slowing and G2/M arrest.
Collectively, our results suggest that acquired resistance to TMZ in glioma cells is not mediated through a single pathway, but that multiple mechanisms may contribute to this phenotype in different cell lines. It will be crucial for adjusted therapy to get a better understanding of all the involved pathways to allow for a personalized relapse therapy once the tumor developed resistance. pyrosequencing analysis of LINE-1 methylation levels (*p<0.05, t-test).
